Drugs /

onalespib

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
onalespib
NCI Definition [1]:
A synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Onalespib selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.

Clinical Trials

View Clinical Trials for onalespib

Onalespib has been investigated in 5 clinical trials, of which 3 are open and 2 are closed. Of the trials investigating onalespib, 4 are phase 1 (3 open) and 1 is phase 2 (0 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for onalespib clinical trials.

Breast carcinoma, fallopian tube carcinoma, and malignant solid tumor are the most common diseases being investigated in onalespib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Onalespib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Onalespib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating onalespib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
at13387, onalespib, (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone, hsp90 inhibitor at13387, at-13387, at 13387, (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone
Drug Categories [2]:
HSP90 inhibitors
Drug Target(s) [2]:
HSP90AA1, HSP90AB1, HSP90B1
NCIT ID [1]:
C129425

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.